<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<?oxy_comment_start author="paulnguyen" timestamp="20141111T135015-0800" comment="C: Need to add TB test to all diagnosises once Labs/Assessments is completed."?>
		<?oxy_comment_start author="paulnguyen" timestamp="20141111T150737-0800" comment="C: Go through indications and update with DXIDs, drug groups, and other aspects to match Simponi." mid="1"?>
		<routedMedId><?oxy_comment_end?><?oxy_comment_end mid="1"?>153035</routedMedId>
		<routedMedName>Stelara subcutaneous</routedMedName>
		<routedGenericName>ustekinumab subcutaneous</routedGenericName>
		<etcIds>
			<etc_id>6200</etc_id>
		</etcIds>
		<medIds>
			<medId>560326</medId>
			<medId>560327</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Psoriatic Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2682</icd9>
			<symbolic>Stelara-PsoriaticArthritis</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Dermatology</name>
					<code>207N00000X</code>
				</prescriber>
				<prescriber>
					<name>Rheumatologist</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Severe Infection</name>
					<code>22.413</code>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>allorder</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.20909|02.16551|02.6260|02.22470</codeValues>
								<selectedListName>Disease Modifying Anti-Rheumatoid Drugs (DMARD)</selectedListName>
								<selectedListClassCode>09.3965</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.16772|02.150396|02.16554|02.152287|02.64713</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.164880|02.164878|02.164879|02.15402|02.94519|02.154546|02.166545|02.150450|02.94107|02.150652|02.95020|02.9755|02.11314|02.150614|02.144377</codeValues>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.154223|02.154650|02.16772|02.144657|02.144769|02.167140|02.147784|02.152021|02.16554|02.152287|02.164798</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165329|02.22175|02.156713|02.94819|02.165957|02.165956|02.5206|02.162865</codeValues>
								<selectedListName>Non-TNF Biologic DMARD</selectedListName>
								<selectedListClassCode>16.16</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.152794</codeValues>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>45 mg subcutaneously at weeks 0 and 4, then 45 mg once every 12 weeks.</text>
				<text>Members with concurrent moderate-to-severe plaque psoriasis weighing > 100 kg (220 lbs): 90 mg subcutaneously weeks 0 and 4, then 90 mg subcutaneously once every 12 weeks.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>560326</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>2 syringes for the first 4 weeks, then 1 syringe every 12 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>1 syringe every 12 weeks</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>560327</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>2 syringes for the first 4 weeks, then 1 syringe every 12 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>1 syringe every 12 weeks</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc; 2012</reference>
				<reference>Gottlieb A, Korman NJ, Gordon KB, et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2.  Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.  J Am Acad Dermatol.  2009; 58: 851-64.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
		<diagnosis>
			<?oxy_comment_start author="paulnguyen" timestamp="20141209T113824-0800" comment="C: Severity is determined by % of body surface area affected (moderate is 3-10% and severe is &gt;10%), as well as, locatoin of lesions, effect on the member&apos;s quality of life and ability to funciton.  See 2010 pocket guide.

MCG&apos;s criteria for severity is based on BSA."?>
			<fqn><?oxy_comment_end?>Moderate to Severe Plaque Psoriasis</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13956</icd9>
			<symbolic>Humira-PlaquePsoriasis</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Dermatology</name>
					<code>207N00000X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Severe Infection</name>
					<code>22.413</code>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>allorder</numRequired>
						<treatment>
							<treatmentLine>
								<?oxy_comment_start author="paulnguyen" timestamp="20141204T145509-0800" comment="C: No concurrent phototherapy with Stelara."?>
								<option><?oxy_comment_end?>WITH</option>
								<interventionType>drug</interventionType>
								<name>UV Phototherapy</name>
								<codeValues>24.96900|24.96910|24.96912|24.96913</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.5571|02.5645|02.20252|02.20909</codeValues>
								<selectedListName>systemic antipsoriatic agents</selectedListName>
								<selectedListClassCode>16.15</selectedListClassCode>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<?oxy_comment_start author="paulnguyen" timestamp="20141209T123510-0800" comment="C: Otezla was not included."?>
								<option><?oxy_comment_end?>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.16772|02.16554|02.64713</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.164880|02.164878|02.164879|02.15402|02.94519|02.154546|02.166545|02.150450|02.94107|02.150652|02.95020|02.9755|02.11314|02.150614|02.144377</codeValues>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.154223|02.154650|02.16772|02.144657|02.144769|02.167140|02.147784|02.152021|02.16554|02.152287|02.164798</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165329|02.22175|02.156713|02.94819|02.165957|02.165956|02.5206|02.162865</codeValues>
								<selectedListName>Non-TNF Biologic DMARD</selectedListName>
								<selectedListClassCode>16.16</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.152794</codeValues>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name>UV Phototherapy</name>
								<codeValues>24.96900|24.96910|24.96912|24.96913|24.96920|24.96921|24.96922</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>Members weighing ≤ 100 kg (220 lbs): 45 mg subcutaneously at weeks 0 and 4, then 45 mg subcutaneously once every 12 weeks.</text>
				<text>Members weighing > 100 kg (220 lbs): 90 mg subcutaneously at weeks 0 and 4, then 90 mg subcutaneously once every 12 weeks.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>560326</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>2 syringes for the first 4 weeks, then 1 syringe every 12 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>1 syringe every 12 weeks</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>560327</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>2 syringes for the first 4 weeks, then 1 syringe every 12 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>1 syringe every 12 weeks</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc; 2012</reference>
				<reference>Hsu S, Papp KA, Lebwohl MG, et al.  Consensus Guidelines for the Management of Plaque Psoriasis.  Arch Dermatol.  2012; 148: 95-102.  DOI 10.1001/archdermatol.2011.1410</reference>
				<reference>Voorhees AV, Feldman SR, Koo JYM, et al.  The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment algorithms and management options.  National Psoriasis Foundation.  http://www.psoriasis.org/document.doc?id=354.  Published 2009.  Accessed September 4, 2014.</reference>
				<reference>Mrowietz U, Kragballe K, Reich K, et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.  Arch Dermatol Res.  2011; 303: 1–10. DOI 10.1007/s00403-010-1080-1</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
		<diagnosis>
			<?oxy_comment_start author="paulnguyen" timestamp="20141208T122241-0800" comment="C: Stelara is only for the maintenance phase.  Patient&apos;s must have undergone successful induction, which requires using the IV form, first.  Refer to the original NEJM article.

See the study design in the original article in NEJM for criteria to add to assessments/labs and exclusion criteria (see Patients under the Methods section)."?>
			<fqn><?oxy_comment_end?>Crohn's Disease-moderate to severe</fqn>
			<age>
				<ageRangeType>gt</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2089</icd9>
			<symbolic>Humira-CrohnsDisease</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe active</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Gastroenterology</name>
					<code>207RG0100X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Severe Infection</name>
					<code>22.413</code>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>all</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.64713|02.16554</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.164880|02.164878|02.164879|02.15402|02.94519|02.154546|02.166545|02.150450|02.94107|02.150652|02.95020|02.9755|02.11314|02.150614|02.144377</codeValues>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.150396|02.154223|02.154650|02.16772|02.144657|02.144769|02.167140|02.147784|02.152021|02.16554|02.152287|02.164798</codeValues>
								<selectedListName>Tumor Necrosis Factor (TNF) Inhibitors</selectedListName>
								<selectedListClassCode>16.13</selectedListClassCode>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165329|02.22175|02.156713|02.94819|02.165957|02.165956|02.5206|02.162865</codeValues>
								<selectedListName>Non-TNF Biologic DMARD</selectedListName>
								<selectedListClassCode>16.16</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.152794</codeValues>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text>6 mg/kg IV at week 0, followed by 90 mg subcutaneously every 8 weeks starting at week 8.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<?oxy_comment_start author="paulnguyen" timestamp="20150209T103543-0800" comment="C: Update the QL with info on initiating therapy once the Med IDs are added.  Set the QL based on a 100 kg member."?>
				<qlimit>
					<?oxy_comment_end?>
					<medId>560327</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>1 syringe every 8 weeks</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>1 syringe every 8 weeks</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Sandborn WJ, Gasink C, Gao L-L, et al.  Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease.  N Eng J Med.  2012; 367: 1519-28.  DOI: 10.1056/NEJMoa1203572</reference>
				<reference>Lichtenstein GR, Hanauer SB, Sandborn WJ.  Management of Crohn's Disease in Adutls.  Am J Gastroenterol.  2009; 104: 465-83.  doi: 10.1038/ajg.2008.168</reference>
				<reference>Sandborn WJ, Feagan BG, Lichtenstein GR.  Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.  Aliment Pharmacol Ther.  2007; 26: 987-1003.</reference>
				<reference>Thomson ABR, Gupta M, Freeman HJ.  Use of the tumor necrosis factor-blockers for Crohn's disease.  World J Gastroenterol.  2012; 18: 4823-54.  doi:10.3748/wjg.v18.i35.4823</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
		<listDef>
			<name>Tumor Necrosis Factor (TNF) Inhibitors</name>
			<codeValue>16.13</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Enbrel SureClick subcutaneous</name>
				<codeValue>02.144657</codeValue>
			</listItem>
			<listItem>
				<name>Enbrel subcutaneous</name>
				<codeValue>02.16772</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Powder for Reconstitution subcutaneous</name>
				<codeValue>02.154650</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Starter Kit subcutaneous</name>
				<codeValue>02.154223</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia subcutaneous</name>
				<codeValue>02.150396</codeValue>
			</listItem>
			<listItem>
				<name>Simponi ARIA intravenous</name>
				<codeValue>02.164798</codeValue>
			</listItem>
			<listItem>
				<name>Simponi subcutaneous</name>
				<codeValue>02.152287</codeValue>
			</listItem>
			<listItem>
				<name>Remicade intravenous</name>
				<codeValue>02.16554</codeValue>
			</listItem>
			<listItem>
				<name>Humira Pen subcutaneous</name>
				<codeValue>02.144769</codeValue>
			</listItem>
			<listItem>
				<name>Humira subcutaneous</name>
				<codeValue>02.64713</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Non-TNF Biologic DMARD</name>
			<codeValue>16.16</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>Actemra subcutaneous</name>
				<codeValue>02.165329</codeValue>
			</listItem>
			<listItem>
				<name>Actemra intravenous</name>
				<codeValue>02.153521</codeValue>
			</listItem>
			<listItem>
				<name>Kineret subcutaneous</name>
				<codeValue>02.22175</codeValue>
			</listItem>
			<listItem>
				<name>Orencia subcutaneous</name>
				<codeValue>02.156713</codeValue>
			</listItem>
			<listItem>
				<name>Orencia (with maltose) intravenous</name>
				<codeValue>02.94819</codeValue>
			</listItem>
			<listItem>
				<name>Otezla Starter oral</name>
				<codeValue>02.165957</codeValue>
			</listItem>
			<listItem>
				<name>Otezla oral</name>
				<codeValue>02.165956</codeValue>
			</listItem>
			<listItem>
				<name>Rituxan intravenous</name>
				<codeValue>02.5206</codeValue>
			</listItem>
			<listItem>
				<name>Xeljanz oral</name>
				<codeValue>02.162865</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Live Vaccines</name>
			<codeValue>09.6421</codeValue>
			<listType>drugclass</listType>
			<listItem>
				<name>adenovirus vaccine live type-4 and 7 oral</name>
				<codeValue>02.164880</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-4 oral</name>
				<codeValue>02.164878</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-7 oral</name>
				<codeValue>02.164879</codeValue>
			</listItem>
			<listItem>
				<name>Theracys intravesical</name>
				<codeValue>02.15402</codeValue>
			</listItem>
			<listItem>
				<name>Tice BCG intravesical</name>
				<codeValue>02.94519</codeValue>
			</listItem>
			<listItem>
				<name>BCG vaccine, live (PF) percutaneous</name>
				<codeValue>02.154546</codeValue>
			</listItem>
			<listItem>
				<name>Flumist Quad 2014-2015 nasal</name>
				<codeValue>02.166545</codeValue>
			</listItem>
			<listItem>
				<name>M-M-R II (PF) subcutaneous</name>
				<codeValue>02.150450</codeValue>
			</listItem>
			<listItem>
				<name>ProQuad (PF) subcutaneous</name>
				<codeValue>02.94107</codeValue>
			</listItem>
			<listItem>
				<name>Rotarix oral</name>
				<codeValue>02.150652</codeValue>
			</listItem>
			<listItem>
				<name>RotaTeq Vaccine oral</name>
				<codeValue>02.95020</codeValue>
			</listItem>
			<listItem>
				<name>Vivotif Berna Vaccine oral</name>
				<codeValue>02.9755</codeValue>
			</listItem>
			<listItem>
				<name>Varivax (PF) subcutaneous</name>
				<codeValue>02.11314</codeValue>
			</listItem>
			<listItem>
				<name>YF-Vax (PF) subcutaneous</name>
				<codeValue>02.150614</codeValue>
			</listItem>
			<listItem>
				<name>ZOSTAVAX  subcutaneous</name>
				<codeValue>02.144377</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Anti-inflammatory - Interleukin-1 beta Blockers</name>
			<codeValue>09.6212</codeValue>
			<listType>drugclass</listType>
			<listItem>
				<name>Ilaris (PF) subcutaneous</name>
				<codeValue>02.152794</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>systemic antipsoriatic agents</name>
			<codeValue>16.15</codeValue>
			<listType>adhoc</listType>
			<listItem>
				<name>acitretin oral</name>
				<codeValue>02.5571</codeValue>
			</listItem>
			<listItem>
				<name>cyclosporine oral</name>
				<codeValue>02.5645</codeValue>
			</listItem>
			<listItem>
				<name>cyclosporine modified oral</name>
				<codeValue>02.20252</codeValue>
			</listItem>
			<listItem>
				<name>methotrexate sodium oral</name>
				<codeValue>02.20909</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Disease Modifying Anti-Rheumatoid Drugs (DMARD)</name>
			<codeValue>09.3965</codeValue>
			<?oxy_comment_start author="paulnguyen" timestamp="20141212T104214-0800" comment="C: The text form says &apos;class&apos;.  The error goes away when it is changed to &apos;drugclass&apos;.  See if &apos;class&apos; causes and upload error and if it does, then is it fixed when changed to &apos;drugclass&apos;.
				
Also get an error when selecting &apos;Generic Drug&apos;"?>
			<listType><?oxy_comment_end?>drugclass</listType>
			<listItem>
				<name>methotrexate sodium oral</name>
				<codeValue>02.20909</codeValue>
			</listItem>
			<listItem>
				<name>leflunomide oral</name>
				<codeValue>02.16551</codeValue>
			</listItem>
			<listItem>
				<name>sulfasalazine oral</name>
				<codeValue>02.6260</codeValue>
			</listItem>
			<listItem>
				<name>sulfsalazine EC oral</name>
				<codeValue>02.22470</codeValue>
			</listItem>
		</listDef>
	</lists>
</paload>
